Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | VEGFA | P15692 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | CTSG | P08311 | 1/20 | 0.34 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | XIAP | P98170 | 1/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16400099 | 0.90 | HSD11B1 (0.39) | HSD11B1VEGFAEGLN1ELANECTSG | |
| SCHEMBL16399441 | 0.87 | ELANE (0.40) | HSD11B1ELANECTSGPRTN3ALDH1A1 | |
| SCHEMBL17691475 | 0.87 | HSD11B1 (0.35) | HSD11B1ELANECTSGPRTN3ALDH1A1 | |
| SCHEMBL16401118 | 0.86 | HSD11B1 (0.34) | HSD11B1ELANECTSGPRTN3ALDH1A1 | |
| SCHEMBL17685995 | 0.86 | THRB (0.35) | HSD11B1ELANECTSGPRTN3ALDH1A1 | |
| SCHEMBL16399366 | 0.84 | HSD11B1 (0.40) | HSD11B1VEGFAEGLN1ELANECTSG | |
| SCHEMBL16400119 | 0.82 | ELANE (0.39) | HSD11B1ELANECTSGPRTN3ALDH1A1 | |
| SCHEMBL16400736 | 0.78 | HSD11B1 (0.34) | HSD11B1ELANECTSGPRTN3ALDH1A1 | |
| SCHEMBL16400193 | 0.77 | ELANE (0.40) | HSD11B1ELANECTSGPRTN3ALDH1A1 | |
| SCHEMBL17685948 | 0.77 | THRB (0.35) | HSD11B1ELANECTSGPRTN3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160108039-A1 | TRIAZOLOPYRIDINES AS THROMBIN INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-21 | — | — | US | disclosed |
| US-20160108027-A1 | SUBSTITUTED BENZOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-21 | — | — | US | disclosed |
| US-20160108039-A1 | TRIAZOLOPYRIDINES AS THROMBIN INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-21 | — | — | US | disclosed |
| US-20160108027-A1 | SUBSTITUTED BENZOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-21 | — | — | US | disclosed |
| US-20160108039-A1 | TRIAZOLOPYRIDINES AS THROMBIN INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-21 | — | — | US | disclosed |
| US-20160108027-A1 | SUBSTITUTED BENZOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-21 | — | — | US | disclosed |
| EP-3004086-A1 | SUBSTITUTED BENZOXAZOLES | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-13 | — | — | EP | disclosed |
| EP-3004095-A1 | TRIAZOLOPYRIDINES AS THROMBIN INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISEASES | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014195244-A1 | TRIAZOLOPYRIDINES AS THROMBIN INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-11 | — | — | WO | disclosed |
| WO-2014195230-A1 | SUBSTITUTED BENZOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108027-A1 | SUBSTITUTED BENZOXAZOLES | TBXA2R, XDH, CYP4X1 | HSD11B1 1626/4885VEGFA 1077/4885EGLN1 234/4885 |
| US-20160108039-A1 | TRIAZOLOPYRIDINES AS THROMBIN INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISEASES | PLAT, TFPI, SERPINC1 | HSD11B1 3512/4885VEGFA 2335/4885EGLN1 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.